Abstract
Purpose
The combination of gemcitabine (GEM) and nanoparticle albumin-bound paclitaxel (nab-PTX) is an effective chemotherapeutic regimen for locally advanced and metastatic pancreatic cancer. The dose-limiting toxicities (DLTs) of this treatment are sepsis and neutropenia, while the relative dose intensity (RDI) of GEM is approximately 75% and of nab-PTX is 70–80%. In this study, we evaluated the risk factor(s) regarding treatment suspension, which leads to reduction in the RDI of these agents, enabling appropriate schedule management.
Methods
Two hundred patients with pancreatic cancer who received GEM + nab-PTX were retrospectively investigated. Frequency and risk factor(s) of suspension of the treatment and grade 3/4 neutropenia in the first course were evaluated.
Results
The frequency of treatment suspension in the first course was 61%. The frequency of grade 3/4 neutropenia was 51%, while that of thrombocytopenia was 7.5%. The RDI was 78.0% for GEM and 77.7% for nab-PTX. Univariate and multivariate analyses to identify risk or preventive factors related to treatment suspension suggested that low platelet count at baseline was a risk factor, whereas dose reduction from the treatment initiation was a preventive factor. The most common cause of abeyance was grade 3/4 neutropenia (83.6%), the risk factors of which were low platelet count and age ≥ 65 years at baseline, while dose reduction was a preventive factor.
Conclusion
We found that a low platelet level at baseline was a risk factor, whereas dose reduction from initiation was a preventive factor in regard to treatment suspension and severe neutropenia occurrence in GEM + nab-PTX treatment.
Similar content being viewed by others
Data availability
The datasets used and/or analyzed during the current study are available from the corresponding author upon reasonable request.
References
Yip D, Karapetis C, Strickland A, Steer CB, Goldstein D (2006) Chemotherapy and radiotherapy for inoperable advanced pancreatic cancer. Cochrane Database Syst Rev 19(3):CD002093
Sultana A, Smith CT, Cunningham D, Starling N, Neoptolemos JP, Ghaneh P (2007) Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer. J Clin Oncol 25:2607–2615
Bilimoria KY, Bentrem DJ, Ko CY, Ritchey J, Stewart AK, Winchester DP, Talamonti MS (2007) Validation of the 6th edition AJCC pancreatic cancer staging system: report from the National Cancer Database. Cancer 110:738–744
Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M et al (2013) Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 369:1691–1703
Ueno H, Ikeda M, Ueno M, Mizuno N, Ioka T, Omuro Y, Nakajima TE, Furuse J (2016) Phase I/II study of nab-paclitaxel plus gemcitabine for chemotherapy-naive Japanese patients with metastatic pancreatic cancer. Cancer Chemother Pharmacol 77:595–603
Blomstrand H, Scheibling U, Bratthäll C, Green H, Elander NO (2019) Real world evidence on gemcitabine and nab-paclitaxel combination chemotherapy in advanced pancreatic cancer. BMC Cancer 19:40
van Putten JW, Eppinga P, Erjavec Z, de Leede G, Nabers J, Smeets JB et al (2000) Activity of high-dose epirubicin combined with gemcitabine in advanced non-small-cell lung cancer: a multicenter phase I and II study. Br J Cancer 82:806–811
Cucinotto I, Fiorillo L, Gualtieri S, Arbitrio M, Ciliberto D, Staropoli N et al (2013) Nanoparticle albumin bound Paclitaxel in the treatment of human cancer: nanodelivery reaches prime-time? J Drug Deliv 905091. https://doi.org/10.1155/2013/905091
Von Hoff DD, Ramanathan RK, Borad MJ, Laheru DA, Smith LS, Wood TE et al (2011) Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. J Clin Oncol 29:4548–4554
Kanai M, Morita S, Matsumoto S, Nishimura T, Hatano E, Yazumi S (2009) A history of smoking is inversely correlated with the incidence of gemcitabine-induced neutropenia. Ann Oncol 20:1397–1401
O'Malley M, Healy P, Daignault S, Ramnath N (2013) Cigarette smoking and gemcitabine-induced neutropenia in advanced solid tumors. Oncology 85:216–222
Takeuchi H, Saeki T, Aiba K, Tamura K, Aogi K, Eguchi K, Okita K, Kagami Y, Tanaka R, Nakagawa K, Fujii H, Boku N, Wada M, Akechi T, Udagawa Y, Okawa Y, Onozawa Y, Sasaki H, Shima Y, Shimoyama N, Takeda M, Nishidate T, Yamamoto A, Ikeda T, Hirata K (2016) Japanese Society of Clinical Oncology clinical practice guidelines 2010 for antiemesis in oncology: executive summary. Int J Clin Oncol 21:1–12
Abraxane® (nanoparticle albumin-bound paclitaxel) [package insert on the internet]. Tokyo; Taiho pharmaceutical Co., 2014. http://www.info.pmda.go.jp/downfiles/ph/PDF/400107_4240409D1023_1_12.pdf. Accessed 19 Apr 2019
Tanabe Y, Shimizu C, Hamada A, Hashimoto K, Ikeda K, Nishizawa D, Hasegawa J, Shimomura A, Ozaki Y, Tamura N, Yamamoto H, Yunokawa M, Yonemori K, Takano T, Kawabata H, Tamura K, Fujiwara Y (2017) Paclitaxel-induced sensory peripheral neuropathy is associated with an ABCB1 single nucleotide polymorphism and older age in Japanese. Cancer Chemother Pharmacol 79:1179–1186
Bergmann TK, Brasch-Andersen C, Gréen H, Mirza M, Pedersen RS, Nielsen F, Skougaard K, Wihl J, Keldsen N, Damkier P, Friberg LE, Peterson C, Vach W, Karlsson MO, Brosen K (2011) Impact of CYP2C8*3 on paclitaxel clearance: a population pharmacokinetic and pharmacogenomic study in 93 patients with ovarian cancer. Pharm J 11:113–120
Hertz DL, Roy S, Motsinger-Reif AA, Drobish A, Clark LS, McLeod HL et al (2013) CYP2C8*3 increases risk of neuropathy in breast cancer patients treated with paclitaxel. Ann Oncol 24:1472–1478
Kus T, Aktas G, Kalender ME, Demiryurek AT, Ulasli M, Oztuzcu S, Sevinc A, Kul S, Camci C (2016) Polymorphism of CYP3A4 and ABCB1 genes increase the risk of neuropathy in breast cancer patients treated with paclitaxel and docetaxel. Onco Targets Ther 9:5073–5080
Dai D, Zeldin DC, Blaisdell JA, Chanas B, Coulter SJ, Ghanayem BI, Goldstein JA (2001) Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid. Pharmacogenetics 11:597–607
Henningsson A, Marsh S, Loos WJ, Karlsson MO, Garsa A, Mross K, Mielke S, Viganò L, Locatelli A, Verweij J, Sparreboom A, McLeod H (2005) Association of CYP2C8, CYP3A4, CYP3A5, and ABCB1 polymorphisms with the pharmacokinetics of paclitaxel. Clin Cancer Res 11:8097–8104
Ding X, Chen W, Fan H, Zhu B (2015) Cytidine deaminase polymorphism predicts toxicity of gemcitabine-based chemotherapy. Gene 559:31–37
Hryciuk B, Szymanowski B, Romanowska A, Salt E, Wasąg B, Grala B et al (2018) Severe acute toxicity following gemcitabine administration: a report of four cases with cytidine deaminase polymorphisms evaluation. Oncol Lett 15:1912–1916
Sugiyama E, Kaniwa N, Kim SR, Kikura-Hanajiri R, Hasegawa R, Maekawa K, Saito Y, Ozawa S, Sawada J, Kamatani N, Furuse J, Ishii H, Yoshida T, Ueno H, Okusaka T, Saijo N (2007) Pharmacokinetics of gemcitabine in Japanese cancer patients: the impact of a cytidine deaminase polymorphism. J Clin Oncol 25:32–42
Ueno H, Kaniwa N, Okusaka T, Ikeda M, Morizane C, Kondo S, Sugiyama E, Kim SR, Hasegawa R, Saito Y, Yoshida T, Saijo N, Sawada J (2009) Homozygous CDA*3 is a major cause of life-threatening toxicities in gemcitabine-treated Japanese cancer patients. Br J Cancer 100:870–873
Ozkurt ZN, Yegin ZA, Suyani E, Aki SZ, Acar K, Yagci M et al (2010) Factors affecting stem cell mobilization for autologous hematopoietic stem cell transplantation. J Clin Apher 25:280–286
Nieboer P, de Vries EG, Vellenga E, van der Graaf WT, Mulder NH, Sluiter WJ et al (2004) Factors influencing haematological recovery following high-dose chemotherapy and peripheral stem-cell transplantation for haematological malignancies; 1-year analysis. Eur J Cancer 40:1199–1207
Lee M, Yee J, Kim JY, Kim JY, An SH, Lee KE, Gwak HS (2019) Risk factors for neutropenia and febrile neutropenia following prophylactic pegfilgrastim. Asia Pac J Clin Oncol 15:231–237
Tang NL, Liao CD, Wang X, Mo FK, Chan VT, Ng R et al (2013) Role of pharmacogenetics on adjuvant chemotherapy-induced neutropenia in Chinese breast cancer patients. J Cancer Res Clin Oncol 139:419–427
Kornmann M, Butzer U, Blatter J, Beger HG, Link KH (2000) Pre-clinical evaluation of the activity of gemcitabine as a basis for regional chemotherapy of pancreatic and colorectal cancer. Eur J Surg Oncol 26:583–587
Chang YF, Li LL, Wu CW, Liu TY, Lui WY, P'eng FK et al (1996) Paclitaxel-induced apoptosis in human gastric carcinoma cell lines. Cancer 77:14–18
de Graan AJ, Loos WJ, Friberg LE, Baker SD, van der Bol JM, van Doorn L et al (2012) Influence of smoking on the pharmacokinetics and toxicity profiles of taxane therapy. Clin Cancer Res 18:4425–4432
van der Bol JM, Mathijssen RH, Loos WJ, Friberg LE, van Schaik RH, de Jonge MJ, Planting AS, Verweij J, Sparreboom A, de Jong FA (2007) Cigarette smoking and irinotecan treatment: pharmacokinetic interaction and effects on neutropenia. J Clin Oncol 25:2719–2726
Author information
Authors and Affiliations
Contributions
Participated in research design: YS, TY, and MK
Conducted experiments: YS
Performed data analysis: YS
Wrote or contributed to the writing of the manuscript: YS, TY, MK, YK, and MS
Corresponding author
Ethics declarations
Conflict of interest
YS, MK, YT, and MS have no conflicts of interest. YK reports honoraria from Pfizer, Novartis, and Bayer, and research funding from Eli Lilly, MSD, Ono Pharmaceutical, Novartis, Bayer, Chugai Pharma, Yakult, and Taiho, having provided speaker services for Eli Lilly, Chugai Pharma, Merck Serono, Novartis, Pfizer, Bayer, and Taiho.
Ethical approval
All the procedures performed in studies involving human participants were carried out in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. For this type of study, formal consent is not required.
Consent to participate
For this type of study, formal consent is not required.
Consent for publication
Not applicable.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Saito, Y., Takekuma, Y., Kobayashi, M. et al. Detection of risk factors related to administration suspension and severe neutropenia in gemcitabine and nab-paclitaxel treatment. Support Care Cancer 29, 3277–3285 (2021). https://doi.org/10.1007/s00520-020-05842-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00520-020-05842-x